{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-279068","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.490435+00:00","generated_at":"2026-06-22T05:29:25.649560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing","bullets":["Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.","Cash, equivalents, and marketable securities $655M as of Sep 30, 2022, boosted by July 2022 equity offering of $264.5M gross.","Phase 1/1b trials ongoing for RMC-6236 (RAS MULTI) and RMC-6291 (KRAS G12C); first data expected in 2023.","RMC-9805 (KRAS G12D) first patient dosing expected mid-2023.","Full-year 2022 GAAP net loss guidance reiterated at $260M-$280M; cash runway through 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-279068","json":"https://secwatch.observer/filing/0001193125-22-279068.json","markdown":"https://secwatch.observer/filing/0001193125-22-279068.md","text":"https://secwatch.observer/filing/0001193125-22-279068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/d418464d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:29:25.649560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc51d8536b23121da4a3ea9dfb0363aa94653ed5","claim":"Revolution Medicines, Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}